Skip to main content
61°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Instil Bio
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 13, 2024
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
August 01, 2024
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 10, 2024
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Strategic Update
January 16, 2024
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
December 05, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
November 06, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
June 26, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
January 31, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
January 09, 2023
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
December 08, 2022
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 08, 2022
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
October 31, 2022
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
October 18, 2022
From
Instil Bio
Via
GlobeNewswire
Tickers
TIL
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.